A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

November 16, 2022

Study Completion Date

November 16, 2022

Conditions
Relapsed/Refractory Advanced Solid TumorsRelapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory MyelodysplasiaRelapsed/Refractory MyelofibrosisAdenoid Cystic CarcinomaRelapsed/Refractory Mantle Cell LymphomaRelapsed/Refractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic Leukemia
Interventions
DRUG

PRT543

PRT543 will be administered orally

Trial Locations (23)

10065

Memorial Sloan Kettering Cancer Center, New York

10467

Montefiore Medical Center, The Bronx

15232

UPMC Hillman Cancer Center, Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

19718

Christiana Care Health Services, Christiana Hospital, Newark

28204

Levine Cancer Institute, Charlotte

30912

Georgia Cancer Center at Augusta University, Augusta

32746

Florida Cancer Specialists, Lake Mary

33612

Moffitt Cancer Center, Tampa

34232

Florida Cancer Specialist, Sarasota

37203

PLLC, Nashville

40207

Norton Cancer Institute, St. Matthews Campus, Louisville

43210

The Ohio State University and Wexner Medical Center, Columbus

48109

University of Michigan, Ann Arbor

52242

University of Iowa Hospitals and Clinics, Iowa City

70121

Ochsner Clinic Foundation, New Orleans

77030

MD Anderson Cancer Center, Houston

85234

Banner MD Anderson Cancer Center, Gilbert

94158

UCSF Precision Cancer Medicine Building, San Francisco

98109

Seattle Cancer Care Alliance, Seattle

02215

Dana Farber Cancer Institute, Boston

07962

Atlantic Health System / Morristown Medical Center, Morristown

77030-4009

The University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Prelude Therapeutics

INDUSTRY

NCT03886831 - A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | Biotech Hunter | Biotech Hunter